Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
2014; Elsevier BV; Volume: 124; Issue: 4 Linguagem: Inglês
10.1182/blood-2014-03-566273
ISSN1528-0020
AutoresSteven P. Treon, Christina Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy, Stacey Chuma, Lian Xu, Yang Cao, Guang Yang, Xia Liu, Christopher J. Patterson, Diane Warren, Zachary R. Hunter, Barry Turnbull, Irene M. Ghobrial, Jorge J. Castillo,
Tópico(s)Renal Diseases and Glomerulopathies
ResumoKey Points Carfilzomib, rituximab, and dexamethasone (CaRD) produce overall and CR/VGPR responses in 87% and 36% of frontline WM patients, respectively. CaRD activity was not impacted by MYD88 and CXCR4 mutations and represents a neuropathy-sparing option for treating WM patients.
Referência(s)